1501-Dusp5&Zfp219 to Rejuvenate Aged Antitumor Immunity

This research identifies Dusp5 and Zfp219 as two key genetic regulators that drive T cell exhaustion and failure in older cancer patients. Using CRISPR screens in mouse models, scientists discovered that removing these specific genes helps CD8+ T cells regain their ability to fight tumors within the harsh environment of an aging body. Deleting Dusp5 improves immune responses across all ages by boosting T cell division through the ERK signaling pathway, whereas removing Zfp219 specifically rescues the immune function of aged cells by restoring granzyme production. High levels of ZNF219 in humans are linked to poor survival and weak responses to immunotherapy, suggesting it is a primary driver of age-related immune decline. These findings offer a promising strategy for rejuvenating antitumor immunity in elderly populations by targeting these molecular pathways to improve cancer treatment outcomes.References:Chen A C Y, Ji K Y, Yerinde C, et al. CRISPR screens identify targets to rescue age-related T cell dysfunction in cancer[J]. Cell, 2026.前往小宇宙评论区与主播互动